share_log

HOOKIPA Pharma | 8-K: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma | 8-K: Current report

HOOKIPA Pharma | 8-K：重大事件
美股sec公告 ·  03/22 07:11
Moomoo AI 已提取核心信息
On March 22, 2024, HOOKIPA Pharma Inc. reported its financial results for the fourth quarter and full year of 2023. The announcement highlighted several key developments, including promising preliminary Phase 2 data for HB-200 in treating HPV16+ head and neck cancers, progress on the HB-700 program for KRAS mutated cancers, and advancements in infectious disease programs in partnership with Gilead. HOOKIPA also announced a strong cash position at the end of 2023, with $117.5 million, bolstered by capital raises and collaboration-based milestones. The company is preparing for pivotal trials and IND submissions in 2024. Additionally, HOOKIPA will regain full control of the HB-700 program's intellectual property and rights from Roche as of April 25, 2024. Financially, the company reported an increase in revenue for the year, primarily due to the recognition of upfront and milestone payments from collaborations. However, the company also faced increased research and development expenses and an impairment expense related to the discontinuation of a GMP manufacturing facility project. The net loss for the year increased compared to 2022, reflecting these higher expenses.
On March 22, 2024, HOOKIPA Pharma Inc. reported its financial results for the fourth quarter and full year of 2023. The announcement highlighted several key developments, including promising preliminary Phase 2 data for HB-200 in treating HPV16+ head and neck cancers, progress on the HB-700 program for KRAS mutated cancers, and advancements in infectious disease programs in partnership with Gilead. HOOKIPA also announced a strong cash position at the end of 2023, with $117.5 million, bolstered by capital raises and collaboration-based milestones. The company is preparing for pivotal trials and IND submissions in 2024. Additionally, HOOKIPA will regain full control of the HB-700 program's intellectual property and rights from Roche as of April 25, 2024. Financially, the company reported an increase in revenue for the year, primarily due to the recognition of upfront and milestone payments from collaborations. However, the company also faced increased research and development expenses and an impairment expense related to the discontinuation of a GMP manufacturing facility project. The net loss for the year increased compared to 2022, reflecting these higher expenses.
2024年3月22日，HOOKIPA Pharma Inc.公布了其2023年第四季度和全年财务业绩。该公告强调了几项关键进展，包括令人鼓舞的 HB-200 在治疗 HPV16+ 头颈癌方面的 2 期初步数据、针对 KRAS 突变癌症的 HB-700 计划的进展以及与吉利德合作的传染病项目取得的进展。HOOKIPA还宣布，到2023年底，现金状况强劲，为1.175亿美元，这得益于资金筹集和基于合作的里程碑。该公司正在为2024年的关键试验和IND申请做准备。此外，自2024年4月25日起，HOOKIPA将从罗氏手中夺回对 HB-700 计划知识产权和权利的完全控制权。在财务方面，该公司报告了该年度的收入增长，这主要是由于确认了合作产生的预付款和里程碑付款。但是，该公司还面临增加的研发费用和与停止GMP制造设施项目相关的减值支出。与2022年相比，该年度的净亏损有所增加，这反映了这些更高的支出。
2024年3月22日，HOOKIPA Pharma Inc.公布了其2023年第四季度和全年财务业绩。该公告强调了几项关键进展，包括令人鼓舞的 HB-200 在治疗 HPV16+ 头颈癌方面的 2 期初步数据、针对 KRAS 突变癌症的 HB-700 计划的进展以及与吉利德合作的传染病项目取得的进展。HOOKIPA还宣布，到2023年底，现金状况强劲，为1.175亿美元，这得益于资金筹集和基于合作的里程碑。该公司正在为2024年的关键试验和IND申请做准备。此外，自2024年4月25日起，HOOKIPA将从罗氏手中夺回对 HB-700 计划知识产权和权利的完全控制权。在财务方面，该公司报告了该年度的收入增长，这主要是由于确认了合作产生的预付款和里程碑付款。但是，该公司还面临增加的研发费用和与停止GMP制造设施项目相关的减值支出。与2022年相比，该年度的净亏损有所增加，这反映了这些更高的支出。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息